---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-121856"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:46:10.953696+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Surrozen reports Q3 net loss of $1.4M (vs $10.4M YoY); gets $10M BI milestone for SZN-413

## Summary
- Net loss narrowed to $1.4M from $10.4M in Q3 2023; collaboration revenue $10.0M (BI milestone).
- Cash $31.0M at Sep 30, 2024; plus $10M milestone received Oct 2024 from Boehringer Ingelheim.
- Phase 1b SZN-043 in severe alcohol-associated hepatitis: cohort 1 completed; no SAEs, reduced bilirubin/MELD; PoC data expected H1 2025.
- Nominated wholly-owned preclinical ophthalmology candidates SZN-8141/8143/113 targeting Fzd4; SZN-413 advancing with BI.
- New TCGFB research collaboration for TGF-β antibodies in IPF; up to $6M plus equity warrant of 3.38M shares.

## SEC filing metadata
- accession: 0000950170-24-121856
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017024121856/0000950170-24-121856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017024121856/srzn-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-121856
- JSON: https://secwatch.observer/filing/0000950170-24-121856.json
- Plain text: https://secwatch.observer/filing/0000950170-24-121856.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.